BRAF and melanoma: Around 50% of melanoma patients carry mutations in the BRAF gene and around 30% of patients in the NRAS gene resulting in an over-activation of the mitogen-activated protein kinase (MAPK) pathway,1 making this signalling cascade one of the most important targets for melanoma therapy.2,3